Skip Navigation

COMT inhibitors

Important! You should always read carefully the information leaflet that comes with your medication before you start using it. Always check with your doctor or other healthcare professional before altering any of your medications or taking over-the-counter medications as they can interfere with Parkinson’s medications and may have unwanted side effects. Remember also to tell your doctor if you take over-the-counter drugs that can be bought without a prescription.


What you should know about your medication

Each medication has its own particular properties and important considerations to be aware of. Below are some key aspects to think about before you start taking your medication. Detailed information regarding these can be found in the Patient Information Leaflet (PIL):

  • what is it and what is it used for?
  • special warnings and precautions
  • how to take it
  • possible side effects
  • contraindications (when not to use it)
  • interaction with other medication(s)
  • what to do if you forget to take a dose
  • what to do if you take more than you should
  • possible effects on your ability to drive or use machinery
  • safety in pregnancy and breast-feeding
  • how to store.
Parkinson's medication overview of COMT inhibitors
Generic name Brand name ®

COMT inhibitors

  • Entacapone
  • Tolcapone
  • Co-careldopa / entacapone combination
  • Opicapone
  • Comtess/Comtan
  • Tasmar
  • Stalevo
  • Ongentys

COMT inhibitors

Comtess®/Comtan® tablets contain entacapone and are used together with levodopa to treat Parkinson’s. Comtess®/Comtan® aids levodopa in relieving the symptoms of Parkinson's but has no effect on these symptoms unless taken with levodopa.

Patient Information Leaflet (PIL)

The PIL is the leaflet that is included with a medicine and is a patient-friendly version of the Summary of Product Characteristics. It gives information about taking or using a medicine.

The following links provide detailed, up-to-date information on Comtess®, its handling and use. As information leaflets are approved by the regulatory body in each country in which a medication is licensed – and are therefore too numerous to list – we have included only the UK examples. These links go to the Electronic Medicines Compendium (eMC) website.

Summary of Product Characteristics (SPC)

The SPC is used by healthcare professionals and explains how to use and prescribe a medicine.

European Public Assessment Report (EPAR)

EPARs are full scientific assessment reports of medicines authorised at a European Union level.

Links below go to the European Medicines Agency (EMA) website. The European Medicines Agency is a decentralised agency of the European Union, located in London. The Agency is responsible for the scientific evaluation of medicines developed by pharmaceutical companies for use in the European Union.

The EMA publishes an EPAR for every medicine granted a central marketing authorisation by the European Commission following an assessment by the EMA's Committee for Medicinal Products for Human Use (CHMP). EPARs are full scientific assessment reports of medicines authorised at a European Union level. 

  • Comtess® European Public Assessment Report (EPAR) - Read report
  • Comtan® European Public Assessment Report (EPAR) - Read report

Ongentys is used in addition to levodopa (a medicine commonly used to treat the symptoms of Parkinson’s) and DOPA decarboxylase inhibitors (DDCI - other medicines for Parkinson’s). It is used in patients with Parkinson’s who experience ‘motor fluctuations’. 

Ongentys contains the active substance opicapone. 

Patient Information Leaflet (PIL)

The PIL is the leaflet that is included with a medicine and is a patient-friendly version of the Summary of Product Characteristics. It gives information about taking or using a medicine.

The following links provide detailed, up-to-date information on Ongentys®, its handling and use. As information leaflets are approved by the regulatory body in each country in which a medication is licensed – and are therefore too numerous to list – we have included only the UK examples. These links go to the Electronic Medicines Compendium (eMC) website.

Summary of Product Characteristics (SPC)

The SPC is used by healthcare professionals and explains how to use and prescribe a medicine.

European Public Assessment Report (EPAR)

EPARs are full scientific assessment reports of medicines authorised at a European Union level.

Links below go to the European Medicines Agency (EMA) website. The European Medicines Agency is a decentralised agency of the European Union, located in London. The Agency is responsible for the scientific evaluation of medicines developed by pharmaceutical companies for use in the European Union.

The EMA publishes an EPAR for every medicine granted a central marketing authorisation by the European Commission following an assessment by the EMA's Committee for Medicinal Products for Human Use (CHMP). EPARs are full scientific assessment reports of medicines authorised at a European Union level. 

  • Ongentys European Public Assessment Report (EPAR) - Read report

Stalevo® contains three active substances (levodopa, carbidopa and entacapone) in one film-coated tablet. Stalevo® is used for the treatment of Parkinson’s.

Parkinson’s is caused by low levels of a substance called dopamine in the brain. Levodopa increases the amount of dopamine and therefore reduces the symptoms of Parkinson’s. Carbidopa and entacapone improve the antiparkinson effects of levodopa.

 

Patient Information Leaflet (PIL)

The PIL is the leaflet that is included with a medicine and is a patient-friendly version of the Summary of Product Characteristics. It gives information about taking or using a medicine.

The following links provide detailed, up-to-date information on Stalevo®, its handling and use.

As information leaflets are approved by the regulatory body in each country in which a medication is licensed – and are therefore too numerous to list – we have included only the UK examples. These links go to the Electronic Medicines Compendium (eMC) website.

Summary of Product Characteristics (SPC)

The SPC is used by healthcare professionals and explains how to use and prescribe a medicine.

European Public Assessment Report (EPAR)

EPARs are full scientific assessment reports of medicines authorised at a European Union level.

Links below go to the European Medicines Agency (EMA) website. The European Medicines Agency is a decentralised agency of the European Union, located in London. The Agency is responsible for the scientific evaluation of medicines developed by pharmaceutical companies for use in the European Union.

The EMA publishes an EPAR for every medicine granted a central marketing authorisation by the European Commission following an assessment by the EMA's Committee for Medicinal Products for Human Use (CHMP). EPARs are full scientific assessment reports of medicines authorised at a European Union level. 

  • Stalevo® European Public Assessment Report (EPAR) - Read report

For the treatment of Parkinson´s, Tasmar® is used together with levodopa (as levodopa/benserazide or levodopa/carbidopa). Tasmar® is used when all other alternative medicines cannot stabilise your Parkinson’s.

A natural protein (enzyme) in your body, the (COMT) Catechol-Omethyltransferase breaks down the levodopa. Tasmar ® blocks this enzyme and so slows the breakdown of levodopa. This means when it is taken together with levodopa (as levodopa/benserazide or levodopa/carbidopa) you should have an improvement in the symptoms of your Parkinson’s. 

Patient Information Leaflet (PIL)

The PIL is the leaflet that is included with a medicine and is a patient-friendly version of the Summary of Product Characteristics. It gives information about taking or using a medicine.

The following links provide detailed, up-to-date information on Tasmar®, its handling and use. As information leaflets are approved by the regulatory body in each country in which a medication is licensed – and are therefore too numerous to list – we have included only the UK examples. These links go to the Electronic Medicines Compendium (eMC) website

Summary of Product Characteristics (SPC)

The SPC is used by healthcare professionals and explains how to use and prescribe a medicine.

European Public Assessment Report (EPAR)                                                                  

EPARs are full scientific assessment reports of medicines authorised at a European Union level.

Links below go to the European Medicines Agency (EMA) website. The European Medicines Agency is a decentralised agency of the European Union, located in London. The Agency is responsible for the scientific evaluation of medicines developed by pharmaceutical companies for use in the European Union.

The EMA publishes an EPAR for every medicine granted a central marketing authorisation by the European Commission following an assessment by the EMA's Committee for Medicinal Products for Human Use (CHMP). EPARs are full scientific assessment reports of medicines authorised at a European Union level. 

  • Tasmar® European Public Assessment Report (EPAR) - Read report
Back to top